{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:02:37Z","timestamp":1780124557223,"version":"3.54.0"},"reference-count":118,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Prescribing off-label medications for patients undergoing dialysis presents significant clinical challenges that require careful judgement to optimize the risk\u2013benefit ratio. The altered pharmacokinetic profile in this population, characterized by impaired renal elimination, modified non-renal clearance pathways, and complex polypharmacy, has traditionally led to numerous contraindications, not solely due to concerns about drug accumulation but also to prevent serious adverse events. While established dosing protocols exist for certain drug classes, robust pharmacological data remain insufficient for many contemporary medications, leaving clinicians without evidence-based guidance for commonly prescribed authorized therapies in participants without significant chronic renal disease. The categorical off-label medication contraindications in haemodialysis warrants new reconsideration in the light of emerging evidence that has successfully challenged these constraints through well-designed clinical studies and real-world experiences. In this review, we aim to examine the evidence on selected examples of off-label medications previously deemed contraindicated that have been successfully evaluated in patients treated by dialysis, and explore emerging therapeutic agents. Finally, we discuss the clinical, research, methodological, and regulatory barriers that must be addressed to improve evidence-based prescribing in patients on dialysis.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf319","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:44:29Z","timestamp":1760445869000},"source":"Crossref","is-referenced-by-count":1,"title":["Prescription of off-label medications in patients on dialysis: time to challenge contraindications?"],"prefix":"10.1093","volume":"19","author":[{"given":"Maxime","family":"Touzot","sequence":"first","affiliation":[{"name":"Owkin , Biomedical department, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Amato","sequence":"additional","affiliation":[{"name":"Aura Paris Plaisance , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Ridel","sequence":"additional","affiliation":[{"name":"FME Global Medical Office , Fresnes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ure\u00f1a-Torres","sequence":"additional","affiliation":[{"name":"University of Paris Descartes AURA Nord Saint Ouen, Saint Ouen, Francia and Department of Renal Physiology, Necker Hospital, , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2026053002311158100_bib1","article-title":"Safety and efficacy of spironolactone in dialysis-dependent patients: meta-analysis of randomized controlled trials","volume":"9","author":"Liu","year":"2022","journal-title":"Front Med"},{"key":"2026053002311158100_bib2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"2026053002311158100_bib3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/ndt\/gft409","article-title":"Rationale and design of the mineralocorticoid receptor antagonists in end-stage renal disease study (MiREnDa)","volume":"29","author":"Hammer","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026053002311158100_bib4","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/ndt\/gfaa351","article-title":"Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study","volume":"36","author":"Van den Bosch","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026053002311158100_bib5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40262-025-01476-6","article-title":"Population pharmacokinetic modelling of Apixaban in end-stage kidney disease patients with atrial fibrillation receiving haemodialysis","volume":"64","author":"Konecki","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026053002311158100_bib6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1681\/ASN.2019060579","article-title":"Multicenter randomized controlled trial of Vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie study","volume":"31","author":"de Vriese","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026053002311158100_bib7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.05.010","article-title":"Effects of renal failure on drug transport and metabolism","volume":"109","author":"Sun","year":"2006","journal-title":"Pharmacol Ther"},{"key":"2026053002311158100_bib8","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1517\/17425255.2014.931371","article-title":"Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis","volume":"10","author":"Velenosi","year":"2014","journal-title":"Expert Opin Drug Metabol Toxicol"},{"key":"2026053002311158100_bib9","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/0091270011413588","article-title":"Current understanding of drug disposition in kidney disease","volume":"52","author":"Naud","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"2026053002311158100_bib10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2009.147","article-title":"Pharmacokinetic studies in hemodialysis patients","volume":"86","author":"Atkinson","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"2026053002311158100_bib11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/j.1552-4604.1994.tb03973.x","article-title":"Drug dosing in renal insufficiency","volume":"34","author":"Talbert","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"2026053002311158100_bib12","first-page":"800","article-title":"Vaccination and chronic kidney disease","volume":"23","author":"N.J","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2026053002311158100_bib13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2215\/CJN.00340118","article-title":"Clinical pharmacokinetics in kidney disease: fundamental principles","volume":"13","author":"Lea-Henry","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026053002311158100_bib14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.34067\/KID.0000000000000447","article-title":"Polypharmacy in patients with CKD: a systematic review and meta-analysis","volume":"5","author":"Oosting","year":"2024","journal-title":"Kidney360"},{"key":"2026053002311158100_bib15","doi-asserted-by":"publisher","first-page":"100020","DOI":"10.1016\/j.crphar.2021.100020","article-title":"Drug-drug interactions in polypharmacy patients: the impact of renal impairment","volume":"2","author":"Papotti","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2026053002311158100_bib16","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1093\/ckj\/sfab120","article-title":"Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls","volume":"14","author":"Van Oosten","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026053002311158100_bib17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1740774516673818","article-title":"Strength of evidence for labeled dosing recommendations in renal impairment","volume":"14","author":"Gagne","year":"2017","journal-title":"Clinical Trials"},{"key":"2026053002311158100_bib18","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/jcpt.13583","article-title":"Comparison of antimicrobial dosing recommendations in patients receiving intermittent hemodialysis among drug information resources","volume":"47","author":"Lewis","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2026053002311158100_bib19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2215\/CJN.07470717","article-title":"\u03b2-blocker dialyzability in maintenance hemodialysis patients a randomized clinical trial","volume":"13","author":"Tieu","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026053002311158100_bib20","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/ajkd.2002.36331","article-title":"Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (clexane), and danaparoid sodium (orgaran) in stable chronic hemodialysis patients","volume":"40","author":"Polkinghorne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2026053002311158100_bib21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2026053002311158100_bib22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1681\/ASN.2018050515","article-title":"Quantity and reporting quality of kidney research","volume":"30","author":"Chatzimanouil","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026053002311158100_bib23","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/ndt\/gfz023","article-title":"Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials","volume":"34","author":"Zoccali","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2026053002311158100_bib24","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1002\/cam4.5171","article-title":"Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer","volume":"12","author":"Delaye","year":"2023","journal-title":"Cancer Med"},{"key":"2026053002311158100_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1055\/s-0037-1621715","article-title":"Direct oral anticoagulants in end-stage renal disease","volume":"44","author":"Klil-Drori","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"2026053002311158100_bib26","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.ekir.2022.06.005","article-title":"Improving cancer care for patients with CKD: the need for changes in clinical trials","volume":"7","author":"Sprangers","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026053002311158100_bib27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"2026053002311158100_bib28","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"2026053002311158100_bib29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.amjcard.2015.06.024","article-title":"Cardiovascular and renal outcomes trials\u2014is there a difference?","volume":"116","author":"Raggi","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026053002311158100_bib30","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/sj.ki.5001896","article-title":"Lost in publication: half of all renal practice evidence is published in non-renal journals","volume":"70","author":"Garg","year":"2006","journal-title":"Kidney Int"},{"key":"2026053002311158100_bib31"},{"key":"2026053002311158100_bib32","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1093\/ndt\/gfab072","article-title":"Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease","volume":"37","author":"Sise","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026053002311158100_bib33","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2026053002311158100_bib34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S2468-1253(19)30417-0","article-title":"Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study","volume":"5","author":"Lawitz","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026053002311158100_bib35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2019","journal-title":"Virol J"},{"key":"2026053002311158100_bib36","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12\u202fweeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J Hepatol"},{"key":"2026053002311158100_bib37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12664-018-0833-1","article-title":"Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis","volume":"37","author":"Mehta","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"2026053002311158100_bib38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/apt.14429","article-title":"Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis","volume":"47","author":"He","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026053002311158100_bib39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease","volume":"63","author":"Kalyan Ram","year":"2015","journal-title":"J Hepatol"},{"key":"2026053002311158100_bib40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J Hepatol"},{"key":"2026053002311158100_bib41","doi-asserted-by":"publisher","first-page":"14332","DOI":"10.1038\/s41598-020-71205-5","article-title":"Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis","volume":"10","author":"Shehadeh","year":"2020","journal-title":"Sci Rep"},{"key":"2026053002311158100_bib42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12959-019-0211-y","article-title":"Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study","volume":"17","author":"Laugesen","year":"2019","journal-title":"Thromb J"},{"key":"2026053002311158100_bib43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","article-title":"Pros and cons of new oral anticoagulants","volume":"2013","author":"Bauer","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026053002311158100_bib44","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF","volume":"67","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026053002311158100_bib45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1060028016689265","article-title":"Filtering out use of DOACs in hemodialysis","volume":"51","author":"Dager","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2026053002311158100_bib46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fcvm.2022.847286","article-title":"Direct oral anticoagulants vs. warfarin in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis","volume":"9","author":"Elfar","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026053002311158100_bib47","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"2026053002311158100_bib48","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"2026053002311158100_bib49","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"key":"2026053002311158100_bib50","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/1060028017694654","article-title":"Safety outcomes of Apixaban compared with Warfarin in patients with end-stage renal disease","volume":"51","author":"Sarratt","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2026053002311158100_bib51","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/hdi.12773","article-title":"Elimination of intravenous alendronate by hemodialysis: a kinetic study","volume":"23","author":"Iseri","year":"2019","journal-title":"Hemodial Int"},{"key":"2026053002311158100_bib52","doi-asserted-by":"publisher","first-page":"167","DOI":"10.7326\/ANNALS-24-03237","article-title":"Cardiovascular safety and fracture prevention effectiveness of denosumab versus oral bisphosphonates in patients receiving dialysis\u202f: a target trial emulation","volume":"178","author":"Masuda","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026053002311158100_bib53","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"key":"2026053002311158100_bib54","doi-asserted-by":"publisher","first-page":"450","DOI":"10.5301\/jn.5000188","article-title":"Bisphosphonate therapy in renal osteodystrophy\u2014a review","volume":"26","author":"Bergner","year":"2013","journal-title":"J Nephrol"},{"key":"2026053002311158100_bib55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/pharmacy8020059","article-title":"Contrasting PTH response of denosumab use in dialysis patients: a report of 2 cases","volume":"8","author":"Jang","year":"2020","journal-title":"pharm"},{"key":"2026053002311158100_bib56","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","article-title":"Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies","volume":"29","author":"Thongprayoon","year":"2018","journal-title":"Osteoporos Int"},{"key":"2026053002311158100_bib57","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2026053002311158100_bib58","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/jbmr.4409","article-title":"Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk (ARCH) Trial","volume":"36","author":"Brown","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2026053002311158100_bib59","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2026053002311158100_bib60","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000341864","article-title":"Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study","volume":"36","author":"Mitsopoulos","year":"2012","journal-title":"Am J Nephrol"},{"key":"2026053002311158100_bib61","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000316708","article-title":"Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study","volume":"33","author":"Cejka","year":"2010","journal-title":"Kidney Blood Pressure Res"},{"key":"2026053002311158100_bib62","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/1744-9987.12867","article-title":"Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: a pilot study","volume":"24","author":"Yamamoto","year":"2020","journal-title":"Therapeutic Apheresis Dialysis"},{"key":"2026053002311158100_bib63","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","article-title":"Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial","volume":"35","author":"Bilezikian","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026053002311158100_bib64","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/jcph.2050","article-title":"Influence of renal function on pharmacokinetics, pharmacodynamics, and safety of a single dose of Romosozumab","volume":"62","author":"Hsu","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"2026053002311158100_bib65","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00198-022-06534-4","article-title":"Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis","volume":"33","author":"Suzuki","year":"2022","journal-title":"Osteoporos Int"},{"key":"2026053002311158100_bib66","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease. A randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026053002311158100_bib67","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"2026053002311158100_bib68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","article-title":"Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction","volume":"3","author":"Udelson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026053002311158100_bib69","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/clc.20838","article-title":"Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?","volume":"33","author":"Chua","year":"2010","journal-title":"Clin Cardiol"},{"key":"2026053002311158100_bib70","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/20543581251348187","article-title":"The Aldosterone blockade for health improvement evaluation in end-stage renal disease (ACHIEVE) trial: rationale and clinical research protocol","volume":"3","author":"Walsh","year":"2025","journal-title":"Can J Kidney Health Dis"},{"key":"2026053002311158100_bib71","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","article-title":"Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis","volume":"406","author":"Rossignol","year":"2025","journal-title":"Lancet"},{"key":"2026053002311158100_bib72","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.jacc.2024.03.426","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function","volume":"83","author":"Matsumoto","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026053002311158100_bib73","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"2026053002311158100_bib74","first-page":"1692","article-title":"Sacubitril\/valsartan in patients with heart failure and deterioration in eGFR to &lt;30\u00a0mL\/min\/1.73 m2","volume":"12","author":"Chatur","year":"2024","journal-title":"JACC: Heart Fail"},{"key":"2026053002311158100_bib75","doi-asserted-by":"publisher","first-page":"e2429237","DOI":"10.1001\/jamanetworkopen.2024.29237","article-title":"Sacubitril-valsartan in patients requiring hemodialysis","volume":"7","author":"Le","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026053002311158100_bib76","doi-asserted-by":"publisher","first-page":"173444","DOI":"10.1016\/j.ejphar.2020.173444","article-title":"Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis","volume":"884","author":"Kang","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2026053002311158100_bib77","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ndt\/gfg048","article-title":"Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients","volume":"18","author":"Lins","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2026053002311158100_bib78","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.1046\/j.1523-1755.1999.07157.x","article-title":"Effect of simvastatin on the lipid profile of hemodialysis patients","volume":"56","author":"Nishikawa","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"2026053002311158100_bib79","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"2026053002311158100_bib80","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2026053002311158100_bib81","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/ATVBAHA.113.301301","article-title":"Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation","volume":"34","author":"Chen","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026053002311158100_bib82","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1001\/jama.2009.1800","article-title":"Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention","volume":"302","author":"Tsai","year":"2009","journal-title":"JAMA"},{"key":"2026053002311158100_bib83","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2125.2004.02253.x","article-title":"Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes","volume":"59","author":"Green","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"2026053002311158100_bib84","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1592\/phco.27.10.1347","article-title":"Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety","volume":"27","author":"Lachish","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2026053002311158100_bib85"},{"key":"2026053002311158100_bib86","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1016\/j.jtha.2024.07.006","article-title":"Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study","volume":"22","author":"Gouin-Thibault","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2026053002311158100_bib87","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a Human glucagon-like peptide-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2026053002311158100_bib88","doi-asserted-by":"publisher","first-page":"e113468","DOI":"10.1371\/journal.pone.0113468","article-title":"Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study","volume":"9","author":"Osonoi","year":"2014","journal-title":"PLoS ONE"},{"key":"2026053002311158100_bib89","first-page":"206","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blinded, parallel group, randomized trial","volume-title":"Diabetes Care","author":"Idorn","year":"2015"},{"key":"2026053002311158100_bib90","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1111\/dom.16484","article-title":"Efficacy and tolerance of liraglutide for weight loss in obese, type 2 diabetes and haemodialysis patients","volume":"27","author":"Touzot","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026053002311158100_bib91","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1111\/dom.15967","article-title":"Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: a prospective, observational, open-label study","volume":"26","author":"Vanek","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026053002311158100_bib92","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2215\/CJN.0000000750","article-title":"GLP-1 receptor agonist outcomes, safety, and BMI change in a national cohort of dialysis patients","volume":"20","author":"Orandi","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026053002311158100_bib93","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026053002311158100_bib94","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ehf2.14298","article-title":"The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure","volume":"10","author":"Ji","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026053002311158100_bib95","first-page":"807","article-title":"Effects of dapagliflozin in patients with kidney disease, with and without heart failure","volume":"9","author":"McMurray","year":"2021","journal-title":"JACC: Heart Fail"},{"key":"2026053002311158100_bib96","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026053002311158100_bib97","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium\u2013glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026053002311158100_bib98","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinoly"},{"key":"2026053002311158100_bib99","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026053002311158100_bib100","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1681\/ASN.2022030306","article-title":"Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor Dapagliflozin in patients with CKD","volume":"33","author":"Jongs","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026053002311158100_bib101","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026053002311158100_bib102","doi-asserted-by":"publisher","first-page":"109033","DOI":"10.1016\/j.diabres.2021.109033","article-title":"Sodium-glucose cotransporter 2 inhibitors benefit to kidney and cardiovascular outcomes for patients with type 2 diabetes mellitus and chronic kidney disease 3b-4: a systematic review and meta-analysis of randomized clinical trials","volume":"180","author":"Cao","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2026053002311158100_bib103","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026053002311158100_bib104","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR &lt;30\u00a0ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026053002311158100_bib105","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2215\/CJN.0000000000000196","article-title":"Pharmacokinetic properties of dapagliflozin in hemodialysis and peritoneal dialysis patients","volume":"18","author":"Barreto","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026053002311158100_bib106","first-page":"1","article-title":"Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design","volume":"13","author":"Barreto","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"2026053002311158100_bib107","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11095-020-02832-w","article-title":"An integrated dialysis pharmacometric (IDP) model to evaluate the pharmacokinetics in patients undergoing renal replacement therapy","volume":"37","author":"Broeker","year":"2020","journal-title":"Pharm Res"},{"key":"2026053002311158100_bib108","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/17512433.2017.1323632","article-title":"Guidance to develop individual dose recommendations for patients on chronic hemodialysis","volume":"10","author":"Gotta","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026053002311158100_bib109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000479263","article-title":"Expanded hemodialysis therapy: prescription and delivery","volume":"191","author":"Heyne","year":"2017","journal-title":"Contrib Nephrol"},{"key":"2026053002311158100_bib110","doi-asserted-by":"publisher","first-page":"II51","DOI":"10.1093\/ndt\/gfaa005","article-title":"The renal replacement therapy landscape in 2030: reducing the global cardiovascular burden in dialysis patients","volume":"35","author":"Canaud","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2026053002311158100_bib111","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/imj.12291","article-title":"Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources?","volume":"44","author":"Khanal","year":"2014","journal-title":"Intern Med J"},{"key":"2026053002311158100_bib112","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1053\/ajkd.2001.29225","article-title":"Artificial intelligence: a new approach for prescription and monitoring of hemodialysis therapy","volume":"38","author":"Akl","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2026053002311158100_bib113","doi-asserted-by":"publisher","first-page":"e0148938","DOI":"10.1371\/journal.pone.0148938","article-title":"Performance of a predictive model for long-term hemoglobin response to darbepoetin and iron administration in a large cohort of hemodialysis patients","volume":"11","author":"Barbieri","year":"2016","journal-title":"PLoS ONE"},{"key":"2026053002311158100_bib114","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41581-019-0243-3","article-title":"Artificial intelligence approaches to improve kidney care","volume":"16","author":"Rashidi","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2026053002311158100_bib115","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1016\/S2589-7500(21)00208-9","article-title":"The false hope of current approaches to explainable artificial intelligence in health care","volume":"3","author":"Ghassemi","year":"2021","journal-title":"Lancet Digl Health"},{"key":"2026053002311158100_bib116","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease\u2014Improving Global Outcomes (KDIGO) controversies conference","volume":"92","author":"Baigent","year":"2017","journal-title":"Kidney Int"},{"key":"2026053002311158100_bib117","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cpt.2480","article-title":"Use of real-world evidence to drive drug development strategy and inform clinical trial design","volume":"111","author":"Dagenais","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2026053002311158100_bib118","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12874-022-01799-z","article-title":"External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning","volume":"22","author":"Loiseau","year":"2022","journal-title":"BMC Med Res Method"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf319\/64957184\/sfaf319.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/5\/sfaf319\/64957184\/sfaf319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/5\/sfaf319\/64957184\/sfaf319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:31:20Z","timestamp":1780122680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf319\/8304023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":118,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf319","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,10,27]]},"article-number":"sfaf319"}}